Vision-Related Quality of Life in Patients with Diabetic Macular Edema Treated with Intravitreal Aflibercept: The AQUA Study.

[1]  P. Kaiser,et al.  Intravitreal aflibercept for diabetic macular edema. , 2014, Ophthalmology.

[2]  A. Pleil,et al.  Psychometric validation of the visual function questionnaire-25 in patients with diabetic macular edema , 2013, Health and Quality of Life Outcomes.

[3]  H. Wilhelm,et al.  Vision-related quality of life in patients receiving intravitreal ranibizumab injections in routine clinical practice: baseline data from the German OCEAN study , 2016, Health and Quality of Life Outcomes.

[4]  N. Bressler,et al.  Vision-related function after ranibizumab treatment for diabetic macular edema: results from RIDE and RISE. , 2014, Ophthalmology.

[5]  J. Brazier,et al.  Evaluating the Relationship Between Visual Acuity and Utilities in Patients With Diabetic Macular Edema Enrolled in Intravitreal Aflibercept Studies. , 2017, Investigative ophthalmology & visual science.

[6]  Francesco Bandello,et al.  The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. , 2011, Ophthalmology.

[7]  J. Leksell,et al.  Visual functioning and health-related quality of life in diabetic patients about to undergo anti-vascular endothelial growth factor treatment for sight-threatening macular edema. , 2015, Journal of diabetes and its complications.

[8]  S. Rogers,et al.  Association Between Diabetes-Related Eye Complications and Symptoms of Anxiety and Depression. , 2016, JAMA ophthalmology.

[9]  A. Kampik,et al.  [Measuring patient's quality of life in ophthalmology]. , 2003, Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft.

[10]  E. Çelik,et al.  Changes in vision related quality of life in patients with diabetic macular edema: ranibizumab or laser treatment? , 2015, Journal of diabetes and its complications.

[11]  C. Hirneiss.  The impact of a better-seeing eye and a worse-seeing eye on vision-related quality of life , 2014, Clinical ophthalmology.

[12]  A. Neubauer,et al.  Bestimmung der Lebensqualität des Patienten in der Augenheilkunde , 2003, Der Ophthalmologe.

[13]  Gary C. Brown,et al.  Update on Value-Based Medicine , 2013, Current opinion in ophthalmology.

[14]  P. Kaiser,et al.  Intravitreal Aflibercept for Diabetic Macular Edema: 100-Week Results From the VISTA and VIVID Studies. , 2015, Ophthalmology.

[15]  A. Pleil,et al.  Changes in vision- and health-related quality of life in patients with diabetic macular edema treated with pegaptanib sodium or sham. , 2011, Investigative ophthalmology & visual science.

[16]  E. Lamoureux,et al.  Vision-Related Quality of Life Outcomes in the BEVORDEX Study: A Clinical Trial Comparing Ozurdex Sustained Release Dexamethasone Intravitreal Implant and Bevacizumab Treatment for Diabetic Macular Edema. , 2016, Investigative ophthalmology & visual science.

[17]  Christiane,et al.  World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. , 2013, JAMA.

[18]  N. Bressler,et al.  Improved vision-related function after ranibizumab for macular edema after retinal vein occlusion: results from the BRAVO and CRUISE trials. , 2012, Ophthalmology (Rochester, Minn.).

[19]  P. Romero-Aroca,et al.  What Is the Role of Retinal Barriers in Diabetic Macular Edema ? , 2016 .

[20]  Roberta McKean-Cowdin,et al.  Severity of diabetic retinopathy and health-related quality of life: the Los Angeles Latino Eye Study. , 2011, Ophthalmology.

[21]  Wolzt,et al.  World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. , 2003, The Journal of the American College of Dentists.

[22]  P. Kaiser,et al.  Intravitreal Aflibercept for Diabetic Macular Edema: 148-Week Results from the VISTA and VIVID Studies. , 2016, Ophthalmology.

[23]  Prevalence of diabetic retinopathy and cataract in adult patients with type 1 and type 2 diabetes in Russia. , 2009, The review of diabetic studies : RDS.

[24]  Catherine Sudlow,et al.  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.

[25]  P. Romero-Aroca.  Targeting the Pathophysiology of Diabetic Macular Edema , 2010, Diabetes Care.